Ascendia

  MARKET NEWS

TFF Pharmaceuticals & Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing
Lisata Therapeutics Receives Paediatric Investigation Plan Waiver From EMA for Certepetide in Pancreatic Cancer
Coya Therapeutics Announces $5-Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation
GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program Reduces the Important Inflammatory & Fibrotic Drivers in Idiopathic Pulmonary Fibrosis
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases With First Patient Dosed in Phase 2 TRANQUILITY Trial
Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease

  FEATURED EDITORIAL

  COMPANY PROFILE

Oakwood Chemical is a leader in selling high quality reagents to academic, chemical, and pharmaceutical customers for over thirty years. Located in the South Carolina Lowcountry, we have over 10,000 square feet of laboratory space, as well as two large warehouses totaling 200,000 square feet with over 150,000 chemicals in stock. We offer benchtop to production quantities of inorganic and organic reagents, solvents, salts, catalysts, and biochemicals in numerous grades (reagent, anhydrous, ACS, HPLC, LCMS, NMR, USP) and in different amounts (from lab bench to industrial drum sizes). Let us help you in succeeding in this high growth industry. Click here for more.

  EXCLUSIVE ONLINE CONTENT

PlaqueTec & the Babraham Institute Collaborate on Early Phase Target Discovery & Development

PlaqueTec & the Babraham Institute Collaborate on Early Phase Target Discovery & Development

Campus Innovation Award (CIA)-funded project evaluated lead compounds predicted to bind a pro-inflammatory protein discovered by PlaqueTec….

Biopharmaceutical Mega M&A Deals Surge by 71% YoY During Q1 2024

Biopharmaceutical Mega M&A Deals Surge by 71% YoY During Q1 2024

Mergers and acquisitions (M&As) in the biopharmaceutical industry have rebounded with a $76.9 billion increase in total deal value seen from 2022 to 2023. In Q1 2024 alone, biopharmaceutical M&A reached a total deal value of….

ElevateBio Announces New US Patents for Lead Life Edit CRISPR Systems & Adenine Deaminases Enabling Advanced Gene Editing Techniques

ElevateBio Announces New US Patents for Lead Life Edit CRISPR Systems & Adenine Deaminases Enabling Advanced Gene Editing Techniques

ElevateBio is building a robust portfolio of patents protecting its novel technologies while the Company scales as the world’s first integrated genetic medicine foundry….

AbbVie & Gilgamesh Pharmaceuticals Announce Collaboration & Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders

AbbVie & Gilgamesh Pharmaceuticals Announce Collaboration & Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders

Collaboration to leverage AbbVie’s psychiatry expertise and Gilgamesh’s innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders….

Premium Cell Culture Ingredients From Actylis

Premium Cell Culture Ingredients From Actylis

Download the Actylis Cell Culture Ingredients brochure to discover our product list or ask for a sample of a specific product…..

  WHITEPAPERS & WEBINARS

WHITEPAPER - A Holistic Approach to Getting the First Batch Right

WHITEPAPER - A Holistic Approach to Getting the First Batch Right

By: Mark Rauckhorst, Director Supply Chain and Project Management, Vetter Development Service USA. Inc.

Clinical trials are high-visibility milestones for investors, as this is often the first major step toward financial return on what has likely been years of investment …

WHITEPAPER - Continuous Flow - An Emerging Alternative

WHITEPAPER - Continuous Flow - An Emerging Alternative

Pharmaceutical companies have traditionally been risk-averse, often adopting safe and well-established processes due to the conservative stance of regulatory agencies on novel methodologies. However, with the increasing complexity of drug molecules and the demand for newer and harsher reaction conditions, …

WHITEPAPER - Manufacturing of 10-mg Loratadine Self-Emulsifying Drug Delivery System (SEDDS) Tablets by Direct Compression With ABISORB-DC & ABISOL Emulsion Preconcentrate Kit

WHITEPAPER - Manufacturing of 10-mg Loratadine Self-Emulsifying Drug Delivery System (SEDDS) Tablets by Direct Compression With ABISORB-DC & ABISOL Emulsion Preconcentrate Kit

Traditionally, lipid-based drug delivery, including SEDDS, for per-oral dosing have primarily been formulated as soft-gels or liquid-filled hard-gels. With ABISORB-DC, the bioavailability enhancing features of lipid-based drug delivery can be combined with the high-throughput and ease of manufacturing of direct …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

May 29 – Controlled Release
June 5 – Prefilled Syringes